Valuation: Tarsus Pharmaceuticals, Inc.

Market Cap 3.17B 2.85B 2.66B 2.41B 4.53B 302B 4.56B 31.94B 12.47B 157B 11.91B 11.65B 504B P/E 2026 *
-15.1x
P/E 2027 * 542x
Enterprise Value 2.84B 2.55B 2.38B 2.16B 4.05B 270B 4.07B 28.56B 11.15B 140B 10.65B 10.42B 451B EV / Sales 2026 *
3.91x
EV / Sales 2027 * 2.9x
Free-Float
97.31%
Yield 2026 *
-
Yield 2027 * -
1 day+2.08%
1 week-1.79%
Current month-8.04%
1 month-9.58%
3 months+28.84%
6 months-2.06%
Current year-11.71%
1 week 70.03
Extreme 70.03
76.64
1 month 70.03
Extreme 70.03
79.78
Current year 53.89
Extreme 53.89
91.53
1 year 53.89
Extreme 53.89
91.53
3 years 12.57
Extreme 12.57
91.53
5 years 10.8
Extreme 10.8001
91.53
10 years 10.8
Extreme 10.8001
91.53
Manager TitleAgeSince
Chief Executive Officer 48 31/08/2018
Director of Finance/CFO 64 23/04/2023
Chief Tech/Sci/R&D Officer 47 03/11/2024
Director TitleAgeSince
Chairman 48 01/12/2022
Director/Board Member 71 30/11/2019
Director/Board Member 80 31/12/2016
Date Insider Type Main position Quantity % Market Cap. Importance
15/09/26 Exercice

Director

604 0.0014%
15/09/26 Exercice

Director

12,902 0.0294%
15/09/26 Exercice

Director

402 0.0009%
Change 5-day change 1-year change 3-year change Capi.($)
+2.08%-1.79%+3.52%+456.93% 3.11B
+3.62%+1.68%+48.80%+98.41% 1,040B
+2.13%-1.76%+33.04%+61.88% 599B
+3.32%+4.47%+23.72%+91.59% 485B
+3.80%+3.21%+73.99%+41.69% 350B
+3.09%+3.03%+29.59%+45.42% 345B
+2.82%+2.20%+17.90%+40.15% 272B
+3.40%+0.99%-3.44%+12.08% 244B
+3.21%+3.15%+45.01%+49.99% 223B
+3.80%+4.56%+29.59%+97.73% 183B
Average +2.92%+1.53%+30.17%+99.59% 374.59B
Weighted average by Cap. +2.66%+1.53%+36.76%+69.01%

Financials

2026 *2027 *
Net sales 725M 652M 608M 551M 1.03B 68.98B 1.04B 7.3B 2.85B 35.8B 2.72B 2.66B 115B 930M 836M 780M 707M 1.33B 88.51B 1.34B 9.37B 3.66B 45.94B 3.49B 3.42B 148B
Net income -215M -193M -180M -163M -307M -20.46B -309M -2.16B -845M -10.62B -807M -790M -34.15B 9.62M 8.65M 8.07M 7.31M 13.73M 915M 13.82M 96.85M 37.82M 475M 36.11M 35.33M 1.53B
Net Debt -336M -302M -282M -256M -480M -32B -483M -3.39B -1.32B -16.61B -1.26B -1.24B -53.42B -476M -428M -399M -362M -679M -45.26B -683M -4.79B -1.87B -23.49B -1.79B -1.75B -75.56B
Projected Income Statement - Annual - Tarsus Pharmaceuticals, Inc.
Logo Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics, starting with eye care. The Company's lead product candidate, XDEMVY, is a lotilaner ophthalmic solution that targets and eradicates the root cause of Demodex blepharitis, Demodex mite infestation. The active pharmaceutical ingredient (API) of XDEMVY, lotilaner, paralyzes and eradicates mites and other parasites through the inhibition of parasite-specific gamma-aminobutyric acid-gated chloride channels. It is investigating the development of its product candidates to address targeted diseases with medical needs, which include TP-04, a novel ophthalmic gel formulation of lotilaner for the potential treatment of Ocular Rosacea, and TP-05, a novel investigational oral formulation of lotilaner, for potential Lyme disease prophylaxis and community malaria reduction. It is also developing IRX-101, an investigational ocular antiseptic.
Employees
370
Date Price Change Volume
14/10/26 US$72.29 +2.08% 1,166,766
13/10/26 US$70.82 -4.81% 1,632,816
12/10/26 US$74.40 +1.69% 1,463,048
09/10/26 US$73.16 +1.30% 481,753
08/10/26 US$72.22 -1.89% 642,111
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Tarsus Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
72.29USD
Average target price
99.80USD
Spread / Average Target
+38.06%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Tarsus Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. TARS Stock